Drugs in Dev. Hepatology (Liver, Pancreatic, Gall Bladder)
IND Enabling
China 
Lead Product(s) : HPG7233
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HPG7233, an agonist of thyroid hormone receptor beta (THR-β) for the treatment of patients with non-alcoholic steatohepatitis (NASH) and dyslipidemia.
Product Name : HPG7233
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 20, 2023
Lead Product(s) : HPG7233
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ECC4703
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eccogene Announces US IND Approval for THRβ Agonist ECC4703
Details : ECC4703 was discovered from Eccogene's internal drug discovery platform. It is a β-selective, liver targeting THR full agonist. ECC4703 has demonstrated superiority in pre-clinical studies over partial agonist MGL-3196.
Product Name : ECC4703
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 08, 2022
Lead Product(s) : ECC4703
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASC42
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42，an FXR Agonist
Details : ASC42 is an in-house developed，novel non-steroidal, selective, potent Farnesoid X Receptor (FXR) agonist with best-in-class potential. In two NASH animal models, ASC42 demonstrated significant improvements in liver steatosis, inflammation and fibrosis.
Product Name : ASC42
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 13, 2020
Lead Product(s) : ASC42
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASC42
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ASC42 is an in-house developed Farnesoid X Receptor (FXR) agonist. In two NASH animal models, ASC42 demonstrated significant improvements in liver steatosis, inflammation and fibrosis.
Product Name : ASC42
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 14, 2020
Lead Product(s) : ASC42
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASC42
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist
Details : ASC42 is an in-house developed Farnesoid X Receptor (FXR) agonist. In two NASH animal models, ASC42 demonstrated significant improvements in liver steatosis, inflammation and fibrosis.
Product Name : ASC42
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 14, 2020
Lead Product(s) : ASC42
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASC41
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ascletis' THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication
Details : Ascletis Pharma received IND approval from China's National Medical Products Administration (NMPA) for its in-house developed Category 1 Drug ASC41 to conduct clinical trials for Non-alcoholic Steatohepatitis (NASH) indication.
Product Name : ASC41
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 13, 2020
Lead Product(s) : ASC41
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ASC41,ASC40
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA
Details : ASC41 is expected to be used in combination with ASC40, another innovative drug of the Company, for treatment of NASH.
Product Name : ASC41
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 17, 2020
Lead Product(s) : ASC41,ASC40
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
